CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

Pfizer

Status and phase: Completed; Phase 2; Phase 1

Conditions: Carcinoma, Renal Cell

Treatments: Drug: CPG 7909

Study type: Interventional

Funder types: Industry

Identifiers

NCT00043407

CO10, A8501022

C010

Details and patient eligibility

About

CPG 7909 given alone to patients with renal cell cancer after their nephrectomy. CPG 7909 is as a subcutaneous injection once per week for up to 24 weeks. Up to 40 patients will be included in the study.

Enrollment: 42 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Stage IV Renal Cell Carcinoma with lung and/or soft tissue metastasis Nephrectomy Measurable disease by RECIST criteria

Exclusion criteria

CNS, bone or Liver metastasis Tumors that are mainly papillary, chromophobe, medullary, collecting duct, or unclassified Prior immunotherapy, including IL-2 or IFN-alpha

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

42 participants in 1 patient group

CPG 7909 Injection

Experimental group

Treatment:

Drug: CPG 7909